Expression of peripheral blood miRNA-720 and miRNA-1246 can be used as a predictor for outcome in multiple myeloma patients.

Publication date: Available online 10 May 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Yuyue Ren, Xiaoyun Li, Wei Wang, Wanting He, Jinghua Wang, Ying Wang Multiple myeloma(MM) is a heterogeneous disorder, encompassing several related entities that share the common characteristic of being composed of monoclonal plasma cells (PCs). MicroRNAs (miRNAs) are small non-coding RNAs that control the expression of many target messenger RNAs involved in normal cell functions. Two serum microRNAs, miRNA-720 and miRNA-1246, were found to have potential as diagnostic biomarkers in myeloma. Therefore, we investigated a possible correlation of peripheral blood(PB) miRNAs expression with diagnosis, and prognosis. We measured the expression of PB miRNA-720 and miRNA-1246 in 60 newly diagnosed MM patients by quantitative real-time PCR analyses. The expression levels of PB miRNAs are significantly higher in myeloma patients compared with controls, and do not change with age, gender, disease stage, HGB, bone marrow plasma cell percentage, β2-MG, serum albumin, calcium serum, serum creatinine and myeloma protein, and independent of the deletion of chromosome 13, suggesting that the expression levels of PB miRNA-720 and miRNA-1246 can be used as a diagnosis test for myeloma. We first discovered that increased expression of PB miRNA-720 and miRNA-1246 were associated with shorter progression-free survival(PFS), indicating poor prognosis. The miRNAs have a significant value...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research